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Introduction
Although the thrombolysis in myocardial infarction
(TIMI) flow grade is a widely used qualitative measure-
ment in angiographic trials, it is limited by its subjective
and categorical nature. In contrast, the TIMI frame count
(TFC) is a reproducible, objective and quantitative index
of coronary flow1,2. The TFC is derived by counting the
number of cineangiographic frames that elapse between
the leading edge of the contrast injection entering the
proximal portion of a coronary artery and arriving at a
predetermined distal landmark1. Recent reports showed
that the TFC is correlated with coronary flow reserve3,
endothelial function4, stenosis severity in the infarct
artery after infarction, infarct zone regional wall
motion5, and adverse clinical outcomes6–8. In addition,
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SUMMARY
Background: The thrombolysis in myocardial infarction (TIMI) frame count was reported to reflect coronary
blood flow and have prognostic value. However, such data in syndrome X was lacking. The purpose of this
study was to examine the prognostic value of the TIMI frame count in syndrome X patients, compared with the
normal population.
Methods: The TIMI frame count was measured in 2,049 consecutive patients referred for coronary angiography
from March 2003 to February 2005.
Results: Among 308 patients with normal coronary angiograms, 44 undergoing the procedure for electrophys-
iologic studies or valvular heart disease surveys other than angina were designated normal controls. Another 155
patients with positive stress test results were diagnosed as syndrome X. Comparisons of the two groups showed that
the syndrome X patients had higher frame counts in the left anterior descending artery (40.9±15.7 vs. 47.8±25.4;
p<0.05) and left circumflex artery (35.2±11.7 vs. 42.0±18.7; p<0.05). A similar trend was found in the right coro-
nary artery (29.3 ± 13.5 vs. 31.9 ± 15.9; p = 0.2). The TIMI frame count in each artery of the syndrome X group
was related to the patients’ variables (sex, age, and body mass index), clinical variables (medication use, diabetes,
hypertension, hypercholesterolemia, smoking, and family history), and hemodynamic variables (aortic systolic
blood pressure and left ventricular end-diastolic pressure). By multivariate analysis, the TIMI frame counts in
all arteries were significantly higher in women and lower with angiotensin-converting enzyme inhibitor (ACEI)
use (both p < 0.05). The frame count in the left anterior descending was associated with diuretics use (p < 0.05).
Conclusion: Our TIMI frame count data confirm the presence of slow coronary flow in syndrome X patients, espe-
cially women. ACEI use shortens the counts in these patients, suggesting that ACEIs have the potential to correct the
underlying hemodynamic defects in such patients. [International Journal of Gerontology 2008; 2(3): 109–114]
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technical factors, such as the contrast injection rate and
catheter size, were reported to have minimal effects on
the TFC9. Therefore, the TFC is useful for risk stratifica-
tion and decision making for patients with coronary
artery disease.
Among patients undergoing coronary angiographic
examination, cardiac syndrome X (triad of angina-like
chest pain, positive stress test, and angiographically nor-
mal coronary arteries) is quite commonly seen. This dis-
order has been linked to endothelial dysfunction of the
coronary microvasculature10–15. Although the TFC has
been used to assess microvascular dysfunction4, such
data were limited for syndrome X. Therefore, the aim of
this study was to examine the TFC in patients with syn-
drome X and evaluate its relationships with clinical,
angiographic, and hemodynamic variables.
Patients and Methods
Patient population
From March 2003 to February 2005, 2,049 patients
underwent coronary angiography in the catheteriza-
tion laboratory of Mackay Memorial Hospital. Coronary
angiography was performed using a Philips Integris BH
5000 (Philips, Hamburg, Germany) equipped with a car-
diovascular angiography analysis system (CAAS II).
Patients were included in this study if they had a normal
coronary angiogram, i.e., no evidence of any obstructive
coronary artery disease, coronary ectasia or major coro-
nary spasm. Among the 318 patients with normal coro-
nary angiograms, 44 patients who underwent the
procedure for electrophysiologic studies (34 patients) or
valvular heart disease surveys (10 patients) other than
angina were designated normal controls. Another 119
patients were excluded for a lack of angina symptoms or
negative stress tests. The remaining 155 patients with
positive stress tests (transient perfusion defect in a thal-
lium 201 myocardial perfusion scan, transient >1-mm
ST-segment depression during an exercise treadmill test,
or both) and clinical angina or angina-like chest pain
were designated the syndrome X group. All case records
were reviewed for a detailed history, physical examina-
tion, biochemistry parameters, and findings of electro-
cardiograms and/or echocardiographic examination.
TIMI frame counts
The numbers of cineframes were measured using a
frame counter on the cineviewer. The numbers of
cineangiographic frames were recorded at 30 frames
per second. In general, the TFCs in the left anterior
descending artery (LAD) and left circumflex artery (LCX)
were assessed in a right anterior oblique projection with
caudal angulation while that in the right coronary artery
(RCA) was assessed in a left anterior oblique projection
with cranial angulation. The first frame used for evaluat-
ing each TFC was the first frame in which the dye fully
entered the artery with antegrade motion and the last
frame was defined as the frame when the dye first
entered the distal landmark branch as reported previ-
ously1. The landmarks included the distal bifurcation of
the LAD (i.e., the mustache, pitchfork or whale’s tail), the
distal branch of the lateral left ventricular (LV) wall
artery with the longest distance from the coronary
ostium of the LCX, and the first branch of the postero-
lateral artery of the RCA.
Definitions of variables
The clinical variables analyzed included age, sex, 
body mass index (BMI), hypertension (documented
hypertension, all with medical control), diabetes 
mellitus (hemoglobin A1c > 7% or postprandial sugar
> 200 mg/dL), hyperlipidemia (serum total cholesterol
> 230 mg/dL or triglyceride > 165 mg/dL), family history
of premature cardiovascular disease, and smoking. The
hemodynamic variables examined were LV end-diastolic
pressure (LVEDP), LV ejection fraction, and systolic and
diastolic blood pressure. Medicine use included β-
blockers, statins, calcium channel blockers (CCBs), nitrate,
angiotensin-converting enzyme inhibitors (ACEIs), and
diuretics.
Statistical analysis
The TFCs were compared in each artery between the
groups using a t test and in the syndrome X group by
analysis of variance. Univariate analysis of all independ-
ent variables with the TFC in each artery was performed
using the F distribution and curve regression (either
logarithmic or logistic regression), primarily to deter-
mine which variables should enter into the multivariable
curve regression.
Results
Clinical characteristics
As shown in Table 1, the clinical variables of sex, 
age, BMI, diabetes mellitus, smoking, family history of
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premature cardiovascular disease, elevated choles-
terol, angiographic variables of aortic systolic and
diastolic pressure, LVEDP, LV ejection fraction, and other
medicine use were similar between the study groups
except for hypertension, which was more common in
the syndrome X group.
TIMI frame counts
Table 2 shows the TFCs in the three major coronary
arteries. Comparisons of the two groups demonstrated
that the syndrome X patients had higher TFCs in the
LAD (47.8 ± 25.4 vs. 40.9 ± 15.7; p < 0.05) and LCX
(42.0 ± 18.7 vs. 35.2 ± 11.7; p < 0.05) compared with
the controls. A similar trend was found in the RCA
(31.9 ± 15.9 vs. 29.3 ± 13.5; p = 0.2).
Univariate analysis
Table 3 shows the results of the univariate analysis for
each of the three major epicardial arteries in the syn-
drome X patients. The TFC in each artery of the syndrome
X group was related to the patients’ variables (sex, age,
and BMI), clinical variables (medication use, diabetes,
hypertension, hypercholesterolemia, smoking, and fam-
ily history), and hemodynamic variables (aortic systolic
blood pressure and LVEDP), except for aortic diastolic
pressure and CCB use. The crucial variables that dif-
fered significantly for all three arteries were sex, hyper-
tension, BMI, and use of either ACEIs or diuretics.
Multivariate analysis
The results of the multivariable curve regression analy-
sis are shown in Table 4. In all three major epicardial
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Table 1. Baseline characteristics of the syndrome X and normal groups*
Variable Syndrome X (n = 155) Control (n = 44)
Male 76 (49) 23 (52)
Age (yr) 58.2 ± 11.9 59.6 ± 14.1
Hypertension 87 (56)† 14 (31)†
Aortic systolic pressure (mmHg) 139.5 ± 21.4 144.1 ± 34.3
Aortic diastolic pressure (mmHg) 76.8 ± 13.3 76.2 ± 12.9
Smoking 32 (20) 11 (25)
Diabetics mellitus 17 (11) 5 (11)
Hyperlipidemia 29 (19) 6 (14)
Family history 15 (10) 4 (9)
Body mass index (kg/m2) 26.8 ± 4.1 24.5 ± 3.9
LV end-diastolic pressure (mmHg) 17.4 ± 6.5 19.2 ± 8.4
LV ejection fraction (%) 66.4 ± 14.4 62.5 ± 13.3
Medication
β-blockers 65 (42) 14 (32)
CCBs 28 (18) 10 (23)
Statins 15 (10) 4 (9)
ACEIs 36 (23) 12 (27)
Diuretics 39 (25) 13 (30)
*Data are presented as n (%) or mean ± standard deviation; †p < 0.05. LV = left ventricular; CCB = calcium channel blocker; ACEI = angiotensin-
converting enzyme inhibitor.
Table 2. Thrombolysis in myocardial infarction (TIMI) frame
counts in the normal and syndrome X groups*
Control (n = 44) Syndrome X (n = 155) p
TIMI frame count (frames)
LAD 40.9 ± 15.7 47.8 ± 25.4 < 0.05
LCX 35.2 ± 11.7 42.0 ± 18.7 < 0.05
RCA 29.3 ± 13.5 31.9 ± 15.9 0.2
*Data are presented as mean ± standard deviation. LAD = left anterior
descending artery; LCX = left circumflex artery; RCA = right coronary
artery.
coronary arteries, sex and ACEIs use were significantly
associated with the TFC in syndrome X patients (both
p < 0.05). In the LAD, the TFC was also associated with
diuretics use (p < 0.05).
Discussion
The results of this study revealed that patients with syn-
drome X had higher TFCs in all three coronary arteries.
In addition, in patients with syndrome X, the TFCs were
even higher in females, and decreased by treatment
with ACEIs or diuretics. These interesting findings indi-
cate the presence of slow coronary flow in patients with
syndrome X and suggest that the underlying patho-
physiology of syndrome X involves elevation of
microvascular resistance.
Although TFC data were initially used for evaluating
both acute and stable coronary artery disease16, recent
reports have shown that the TFC may be an index of
coronary microvascular behavior, which reflects vascular
resistance17. It is established that a large proportion of
patients with syndrome X have both abnormal
vasodilatory coronary blood flow responses and
increased sensitivity of the coronary microcirculation
to vasoconstrictor stimuli (so-called microvascular
angina)18,19. The higher TFCs in patients with syn-
drome X observed in the present study are consistent
with the idea that coronary microcirculation dysfunc-
tion contributes to the development of syndrome X.
Endothelial dysfunction in syndrome X appears to
be multifactorial and linked to risk factors such as smok-
ing, obesity, hypercholesterolemia, and inflammation11.
In the present study, univariate analysis showed that
hypertension, BMI, and use of ACEIs or diuretics were
powerful predictors of coronary flow in patients with
syndrome X. These findings suggest that many meta-
bolic, neurohumoral and hemodynamic factors can
affect coronary vascular resistance and, thus, alter the
TFC17,20,21. Multivariate analysis showed that the use of
ACEIs in patients with syndrome X was associated with
lower TFCs, consistent with current concepts that ACEIs
are beneficial for patients with this disorder15. However,
we did not observe similar effects with CCBs, β-blockers,
nitrate, and statins, which were also reported to be bene-
ficial15. Our findings that the TFCs in all arteries were
higher in female syndrome X patients may help to
explain why women are more vulnerable to this disorder.
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Table 3. Univariate analysis of the three major epicardial
arteries
Variable
p
LAD LCX RCA
Sex < 0.05 < 0.05 < 0.05
Age NS < 0.05 < 0.05
Hypertension < 0.05 < 0.05 < 0.05
Aortic systolic pressure < 0.05 NS NS
Aortic diastolic pressure NS NS NS
Smoking < 0.05 < 0.05 NS
Diabetics mellitus NS < 0.05 NS
Hyperlipidemia NS < 0.05 < 0.05
Family history of premature < 0.05 NS NS
cardiovascular disease
Body mass index < 0.05 < 0.05 < 0.05
LV end-diastolic pressure NS NS < 0.05
Medication
β-blockers NS < 0.05 < 0.05
CCBs NS NS NS
Statins < 0.05 NS NS
ACEIs < 0.05 < 0.05 < 0.05
Diuretics < 0.05 < 0.05 < 0.05
LAD = left anterior descending artery; LCX = left circumflex artery;
RCA = right coronary artery; NS = not significant; CCB = calcium
channel blocker; ACEI = angiotensin-converting enzyme inhibitor.
Table 4. Multivariate analysis of the thrombolysis in myocar-
dial infarction frame counts in the three major 
epicardial arteries*
Variable R p
LAD
Sex 0.339 < 0.05
Diuretics 0.143 < 0.05
ACEIs 0.046 < 0.05
LCA
Sex 0.315 < 0.05
ACEIs 0.118 < 0.05
RCA
Sex 0.057 < 0.05
ACEIs 0.391 < 0.05
*Variables entered into the multivariate analysis were sex, hypertension,
smoking, aortic systolic pressure, diabetes mellitus, hyperlipidemia,
age, premature family history of premature cardiovascular disease,
left ventricular end-diastolic pressure, b-blockers, statins, ACEIs, cal-
cium channel blockers, and diuretics. LAD = left anterior descending
artery; ACEIs = angiotensin-converting enzyme inhibitors; LCX = left
circumflex artery; RCA = right coronary artery.
Normal TFCs in Taiwan
Our data for the TFCs in three coronary arteries were
higher than prior values reported by Gibson et al.1 To
the best of our knowledge, no such data have previ-
ously been reported for Taiwan. In the report by Gibson
et al.1, the TFCs for the LAD were corrected by dividing
by 1.7 to account for its longer length. This ratio is sim-
ilar to the mean ratio of 1.55 predicted using a three-
dimensional vector algebra method22. In our study, the
equivalent ratio was lower than previously reported
ratios.
One possibility for the discrepancy may be the dif-
ference in age, because the patients in the present study
were older than those in the previous reports. Another
possibility is the relatively small numbers of patients,
and the fact that a substantial portion of the normal
control patients had underlying diseases and were tak-
ing medication. For example, over 30% of the patients 
in the normal control group were being treated with
ACEIs or diuretics, or statins for concomitant hyperten-
sion or hyperlipidemia, respectively. These concomi-
tant diseases and the medications may affect the TFCs.
Because the TFCs of the three coronary arteries varied
widely in the present study, we did not use corrected
TFCs. Further large-scale trials are necessary to clarify
the normal corrected TFCs in Taiwan.
Sex differences in TFCs of patients with 
syndrome X
Our findings that female syndrome X patients had
higher TFCs in all three coronary arteries than male
syndrome X patients are consistent with the preva-
lence of this syndrome, because it is more prevalent in
females. Furthermore, these findings may explain why
women are more vulnerable to this disorder. In post-
menopausal women with syndrome X, estrogen defi-
ciency has been suggested as a pathogenic agent, and
acting via endothelium-dependent and -independent
mechanisms23. This idea is supported by a report that
impaired endothelial function in postmenopausal
women with syndrome X is improved by administration
of 17β-estradiol24.
Effects of medicines on the TFCs of syndrome X
patients
Recent evidence suggests that impaired endothelial
nitric oxide bioavailability may exist in a significant por-
tion of patients with syndrome X21,25,26. ACEIs were
reported to clinically improve myocardial ischemia 
in syndrome X patients21,25. However, conventional
anti-ischemic treatments, such as β-blockers and nitrate,
were found to have poor effectiveness in syndrome X
patients26. A recent report from Taiwan showed that
treatment with enalapril, an ACEI, improved coronary
microvascular function by balancing endothelial nitric
oxide metabolism in syndrome X patients21. In the
present study, we also found that ACEI use was benefi-
cial for patients with syndrome X. In contrast,
although statin therapy was reported to be beneficial
in patients with syndrome X27, treatment with statins
was not found to achieve the same beneficial effects in
the present study. Regarding diuretics, the TFC in the
LAD was higher with diuretic use in the present study.
Diuretics are known to alter ventricular preload,
which is reported to affect coronary flow reserve, there-
fore suggesting that diuretics may affect the TFC20.
In conclusion, our TFC data confirm the presence
of slow coronary flow in syndrome X patients, especially
women. In addition, use of ACEIs shortens the TFCs in
these patients, suggesting that ACEIs can be prescribed
for such patients.
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